Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Alexandra Papaioannou, Aliya Khan, Andre Belanger, William Bensen, David Kendler, Francois Theoret, Mo Amin, Lee Brekke, Michelle Erdmann, Valery Walker & Jonathan D. Adachi. (2015) Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Current Medical Research and Opinion 31:7, pages 1391-1401.
Read now
Read now
Articles from other publishers (6)
José Antonio Sacristán, Esther Artime, Silvia Díaz-Cerezo, Marta Comellas, Lucía Pérez-Carbonell & Luis Lizán. (2022) The Impact of Patient Support Programs in Europe: A Systematic Literature Review. The Patient - Patient-Centered Outcomes Research 15:6, pages 641-654.
Crossref
Crossref
H. Hagino, R. Narita, Y. Yokoyama, M. Watanabe & M. Tomomitsu. (2019) A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis. Osteoporosis International 30:10, pages 2027-2037.
Crossref
Crossref
M.A. van Maren, C.E. Wyers, J.H.M. Driessen, J.V. Visser, F. de Vries, K. van de Wijdeven, S. Gevers, W.F. Lems, M.H. Emmelot-Vonk & J.P.W. van den Bergh. (2019) Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporosis International 30:9, pages 1837-1844.
Crossref
Crossref
Masayo Sato, Mika Tsujimoto, Kenta Kajimoto, Hideyuki Uetake, Hiroo Shimoda & Saeko Fujiwara. (2018) Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS). Archives of Osteoporosis 13:1.
Crossref
Crossref
Bente L. Langdahl, Östen Ljunggren, Claude-Laurent Benhamou, Fernando Marin, George Kapetanos, Tomaz Kocjan, Eric Lespessailles, Nicola Napoli, Tatjana Nikolic, Helmut Petto, Thomas Moll & Erik Lindh. (2016) Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS). Calcified Tissue International 99:3, pages 259-271.
Crossref
Crossref
D.-C. Chan, C. H.-C. Chang, L.-C. Lim, A. J. M. Brnabic, J.-Y. Tsauo, R. Burge, F.-Y. Hsiao, L. Jin, S. Gürbüz & R.-S. Yang. (2016) Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database. Osteoporosis International 27:9, pages 2855-2865.
Crossref
Crossref